Natacyn

(Natamycin)

Phase 3Small molecule

HHarrow Inc

Natacyn is one of 8 small molecule programs targeting Corneal Ulcer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Corneal UlcerActive, not recruiting

Corneal UlcerPhase 3

Active, not recruiting

Competition

Competitive Landscape

17 competitors in Corneal Ulcer

#DrugCompanyPhaseTrials

Levaquin

WWim Janssens

Approved

—2

Antibiotics

MMelinta Therapeutics, Inc.

Approved

1 3

Betadine

BBecton, Dickinson and Company

Phase 2

1 4

Vfend

PPrism Pharmaceuticals

Phase 2

1 5

Natacyn

HHarrow Inc

Phase 3

2 6

Riboflavin

CCornea and Laser Eye Institute

Phase 1

—7

Naltrexone Hydrochloride

EEnsysce Biosciences

Preclinical

1 8

Specific Treatment

AAssistance Publique - Hôpitaux de Paris

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Corneal Ulcer2 trials

Therapeutic Exploratory Study of Comparing Natamycin and Voriconazole to Treat Fungal Corneal Ulcer

Completed·UUniversity of California, San Francisco·Phase 1/2·NCT00557362·120 enrolled

Mycotic Antimicrobial Localized Injection for Treatment of Corneal Ulcers

Completed·UUniversity of California, San Francisco·Phase 3·NCT02731638·70 enrolled

Treatment1 trial

Mycotic Ulcer Treatment Trial I

Completed·UUniversity of California, San Francisco·Phase 3·NCT00996736·323 enrolled

Infection1 trial

Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction

Completed·UUniversity of California, San Francisco·Phase 3·NCT05110001·330 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

NATACYN

NDA NDA050514

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Natamycin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Natamycin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Natamycin. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA050514). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Harrow Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: HHarrow Inc

Natacyn

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Corneal Ulcer2 trials

Treatment1 trial

Infection1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News